C - Chemistry – Metallurgy – 07 – C
Patent
C - Chemistry, Metallurgy
07
C
C07C 49/12 (2006.01) A61K 31/11 (2006.01) A61K 31/12 (2006.01) A61K 31/121 (2006.01) A61P 35/00 (2006.01) C07C 47/02 (2006.01) C12N 9/10 (2006.01) C12N 9/99 (2006.01) C12Q 1/48 (2006.01)
Patent
CA 2353867
Prenylating enzymes are involved in modifying oncoproteins, such as RAS, so that growth of neoplastic cells becomes uncontrolled. Inactivation of such enzymes can prevent uncontrolled growth. .alpha.-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase. The compounds can be designed to enhance affinity and/or specificity for a particular protein substrate.
Les enzymes de prénylation jouent dans la modification des oncoprotéines, les RAS par exemple, un rôle tel que la croissance des cellules néoplasiques devienne incontrôlée. L'inactivation desdites enzymes peut empêcher la croissance non contrôlée. On peut utiliser des composés de .alpha.-dicarbonyle pour modifier par covalence et donc inactiver les enzymes de prénylation telles que la farnésyltransférase et la géranylgéranyltransférase protéiques. Les composés peuvent être conçus pour accroître l'affinité et/ou la spécificité pour une substrat protéique particulier.
Hartman Rosemarie F.
Lefler Scott R.
Okolotowicz Karl J.
Ottersberg Steven R.
Robinson Dale E.
Sim & Mcburney
The Arizona Disease Control Research Commission
LandOfFree
Anticancer agents based on prevention of protein prenylation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticancer agents based on prevention of protein prenylation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticancer agents based on prevention of protein prenylation will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1584139